|
|
Background CC chemokine receptor 5 antagonists are a new class of antiretroviral agents.
Methods We conducted two double-blind, placebo-controlled, phase 3 studies — Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 — with patients who had R5 human immunodeficiency virus type 1 (HIV-1) only. They had been treated with or had resistance to three antiretroviral-drug classes and had HIV-1 RNA levels of more than 5000 copies per milliliter. The patients were randomly assigned to one of three antiretroviral regimens consisting of maraviroc once daily, maraviroc twice daily, or placebo, each of which included optimized background therapy (OBT) based on treatment history and drug-resistance testing. Safety and efficacy were assessed after 48 weeks.
Results A total of 1049 patients received the randomly assigned study drug; the mean baseline HIV-1 RNA level was 72,400 copies per milliliter, and the median CD4 cell count was 169 per cubic millimeter. At 48 weeks, in both studies, the mean change in HIV-1 RNA from baseline was greater with maraviroc than with placebo: –1.66 and –1.82 log10 copies per milliliter with the once-daily and twice-daily regimens, respectively, versus –0.80 with placebo in MOTIVATE 1, and –1.72 and –1.87 log10 copies per milliliter, respectively, versus –0.76 with placebo in MOTIVATE 2. More patients receiving maraviroc once or twice daily had HIV-1 RNA levels of less than 50 copies per milliliter (42% and 47%, respectively, vs. 16% in the placebo group in MOTIVATE 1; 45% in both maraviroc groups vs. 18% in MOTIVATE 2; P<0.001 for both comparisons in each study). The change from baseline in CD4 counts was also greater with maraviroc once or twice daily than with placebo (increases of 113 and 122 per cubic millimeter, respectively, vs. 54 in MOTIVATE 1; increases of 122 and 128 per cubic millimeter, respectively, vs. 69 in MOTIVATE 2; P<0.001 for both comparisons in each study). Frequencies of adverse events were similar among the groups.
Conclusions Maraviroc, as compared with placebo, resulted in significantly greater suppression of HIV-1 and greater increases in CD4 cell counts at 48 weeks in previously treated patients with R5 HIV-1 who were receiving OBT. (ClinicalTrials.gov numbers, NCT00098306
[ClinicalTrials.gov]
and NCT00098722
[ClinicalTrials.gov]
.)
Source Information
From Weill–Cornell Medical College, New York (R.M.G.); Quest Clinical Research and Mount Zion Hospital of the University of California, San Francisco, San Francisco (J.L.); Pfizer Global Research and Development, New London, CT (J.G., M.W.D., H.M.); Centre Hospitalier Universitaire St-Pierre, Brussels (N.C.); Orlando Immunology Center, Orlando, FL (E.D.); Wojewodzki Szpital Zakazny, Warsaw, Poland (A.H.); University of South Florida, College of Medicine, Tampa (J.N.); Fundació Irsicaixa and Hospital Universitari Germans Trias i Pujol, Badalona, Spain (B.C.); Venhälsan, Karolinska University Hospital, Stockholm (A.K.); Wohlfeiler, Piperato, and Associates, North Miami Beach, FL (M.W.); New York (J.B.M.); and Pfizer Global Research and Development, Sandwich, United Kingdom (M.M., J.S., C.R., S.F., E.R.).
Address reprint requests to Dr. Gulick at Weill–Cornell Medical College, Box 566, 525 E. 68th St., New York, NY 10065, or at rgulick{at}med.cornell.edu.
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |
Previous
